Hany A. M. El-Sherief
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hany A. M. El-Sherief has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Ahmed M. Sayed
Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, 62513 Beni Suef, Egypt
1 shared publication- Bahaa Gamal Mohamed Youssif
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt
1 shared publication Basmat Amal M. Said
College of Pharmacy, Al-Mustaqbal University, Babylon, 51001, Iraq
1 shared publicationEid Alatwi
Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Aljouf, Saudi Arabia
1 shared publication- Hani Mohammed Hafez
Pharmacy College, Al-Esraa University, Baghdad 10069, Iraq
1 shared publication - Stefan Bräse
Institute of Biological and Chemical Systems-Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology (KIT), Kaiserstraße 12, 76131 Karlsruhe, Germany
1 shared publication
Latest Publications
- Open Access
- 21 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (12) , 9265-9279
Design, synthesis, antiproliferative activity, and molecular dynamics simulation of pyrazoline-based derivatives as dual EGFR and HER-2 inhibitors
The dual targeting of EGFR and HER2 is an established anticancer strategy. A novel series including two distinct scaffolds, A (chalcone-based compounds, 4a–n) and B (pyrazoline-based compounds, 5a–n), was developed and synthesized. The antiproliferative efficacy of 4a–n and 5a–n was examined against a panel of four cancer cell lines. The findings indicated that pyrazoline derivatives 5a–n exhibited more efficacy than chalcone compounds 4a–n. Compounds 4n, 5d, and 5g were identified as the most effective antiproliferative derivatives. These compounds were further investigated as dual EGFR/Her2 inhibitors. Compound 5d inhibited EGFR-TK and HER2 significantly, with IC50 values of 0.126 and 0.061 μM, respectively. Moreover, compound 5d can induce a percentage of pre-G1 apoptosis by 78.53% in cell cycle analysis and cause early apoptosis with necrosis percent of 5.28. Docking and MD simulation illustrated the significant cytotoxic activity of the 5d compound and how it can be a promising scaffold with anticancer activity.
- 21 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (12) , 9265-9279
Open AccessDesign, synthesis, antiproliferative activity, and molecular dynamics simulation of pyrazoline-based derivatives as dual EGFR and HER-2 inhibitors
The dual targeting of EGFR and HER2 is an established anticancer strategy. A novel series including two distinct scaffolds, A (chalcone-based compounds, 4a–n) and B (pyrazoline-based compounds, 5a–n), was developed and synthesized. The antiproliferative efficacy of 4a–n and 5a–n was examined against a panel of four cancer cell lines. The findings indicated that pyrazoline derivatives 5a–n exhibited more efficacy than chalcone compounds 4a–n. Compounds 4n, 5d, and 5g were identified as the most effective antiproliferative derivatives. These compounds were further investigated as dual EGFR/Her2 inhibitors. Compound 5d inhibited EGFR-TK and HER2 significantly, with IC50 values of 0.126 and 0.061 μM, respectively. Moreover, compound 5d can induce a percentage of pre-G1 apoptosis by 78.53% in cell cycle analysis and cause early apoptosis with necrosis percent of 5.28. Docking and MD simulation illustrated the significant cytotoxic activity of the 5d compound and how it can be a promising scaffold with anticancer activity.